TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia–(Newsfile Corp. – January 2, 2026) – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company“), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to […]
